LitAlert ~~ GeneLit.com

    • A male with primary accessory breast carcinoma in an axilla is strongly suspected of having hereditary breast cancer.
    • Takahashi E, Terata K, Nanjo H, Ishiyama K, Hiroshima Y, Yamaguchi A, Yatsuyanagi M, Kudo C, Wakita A, Takashima S, Sato Y, Imai K, Motoyama S, Minamiya Y.
    • Int Cancer Conf J. 2021 Jan 10;10(2):107-111. doi: 10.1007/s13691-020-00466-8. eCollection 2021 Apr.
    • Germline mutations in apoptosis pathway genes in ovarian cancer; the functional role of a TP53I3 (PIG3) variant in ROS production and DNA repair.
    • Chaudhry SR, Lopes J, Levin NK, Kalpage H, Tainsky MA.
    • Cell Death Discov. 2021 Mar 29;7(1):62. doi: 10.1038/s41420-021-00442-y.
    • Mutations in BRCA1/2 and Other Panel Genes in Patients With Metastatic Breast Cancer -Association With Patient and Disease Characteristics and Effect on Prognosis.
    • Fasching PA, Yadav S, Hu C, Wunderle M, Häberle L, Hart SN, Rübner M, Polley EC, Lee KY, Gnanaolivu RD, Hadji P, Hübner H, Tesch H, Ettl J, Overkamp F, Lux MP, Ekici AB, Volz B, Uhrig S, Lüftner D, Wallwiener M, Müller V, Belleville E, Untch M, Kolberg HC, Beckmann MW, Reis A, Hartmann A, Janni W, Wimberger P, Taran FA, Fehm TN, Wallwiener D, Brucker SY, Schneeweiss A, Hartkopf AD, Couch FJ.
    • J Clin Oncol. 2021 Mar 29:JCO2001200. doi: 10.1200/JCO.20.01200. Epub ahead of print.
    • Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts.
    • Martin M, Ramos-Medina R, Bernat R, García-Saenz JA, Del Monte-Millan M, Alvarez E, Cebollero M, Moreno F, Gonzalez-Haba E, Bueno O, Romero P, Massarrah T, Echavarria I, Jerez Y, Herrero B, Gonzalez Del Val R, Lobato N, Rincon P, Palomero MI, Marquez-Rodas I, Lizarraga S, Asensio F, Lopez-Tarruella S.
    • Sci Rep. 2021 Mar 29;11(1):7064. doi: 10.1038/s41598-021-85962-4.
    • Talazoparib Versus Chemotherapy in Patients with HER2-negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial.
    • Lee KH, Sohn J, Goodwin A, Usari T, Lanzalone S, Im SA, Kim SB.
    • Cancer Res Treat. 2021 Mar 24. doi: 10.4143/crt.2020.1381. Epub ahead of print.